Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
2.330
+0.010 (0.43%)
At close: Apr 28, 2026, 4:00 PM EDT
2.370
+0.040 (1.72%)
After-hours: Apr 28, 2026, 5:31 PM EDT
Kiora Pharmaceuticals Employees
Kiora Pharmaceuticals had 13 employees as of December 31, 2025. The number of employees increased by 1 or 8.33% compared to the previous year.
Employees
13
Change (1Y)
1
Growth (1Y)
8.33%
Revenue / Employee
n/a
Profits / Employee
-$833,473
Market Cap
10.36M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Lunai Bioworks | 29 |
| Imunon | 25 |
| BioLineRx | 24 |
| Bolt Biotherapeutics | 23 |
| CalciMedica | 16 |
| Cellectar Biosciences | 11 |
| Aprea Therapeutics | 8 |
KPRX News
- 14 days ago - Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway - Newsfile Corp
- 26 days ago - Kiora Pharmaceuticals Announces Management Team Changes - Newsfile Corp
- 4 weeks ago - Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Newsfile Corp
- 2 months ago - Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - Newsfile Corp
- 3 months ago - Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile Corp
- 5 months ago - Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders - PRNewsWire